MedTrace Logo

Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH

NCT05860699 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2025-12-03

No results posted yet for this study

Summary

Randomized clinical trial of 11 days Cannabidiol versus placebo as an adjunctive treatment during inpatient alcohol detoxification to improve abstinence in patients with severe alcohol use disorder.

Conditions

  • Severe Alcohol Use Disorder (DSM 5)

Interventions

DRUG

Placebo

Placebo made by the same manufacturer to look like the active pills

DRUG

Half dose CBD

add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 11 days during their inpatient stay

DRUG

Full dose CBD

add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 11 days during their inpatient stay

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Florence Vorspan · Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, AP-HP Inserm UMR-S 1144 Université de Paris FHU NOR-SUD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-08
Primary Completion
2026-05-23
Completion
2026-05-23

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05860699 on ClinicalTrials.gov